Dr. Thomas Jefferson Gernon, MD

Dr. Gernon practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Gernon's NPI, 1548387525, was assigned on March 23, 2007. Dr. Gernon graduated from University Of Washington School Of Medicine in 2005. Dr. Gernon's California license number on file is C139412.

Dr. Gernon's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Gernon's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Gernon to 1 more group practice or clinic and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gernon practices, 2 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Gernon's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Gernon is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dmand AI has Dr. Gernon's licenses on file in 4 states: California, Arizona, Washington and Michigan.

Dmand AI lists ear infection, endoscopic sinus surgery, larynx and vocal cord disease and thyroid surgery among the conditions Dr. Gernon treats.

CMS data shows 500 Medicare services from Dr. Gernon across 8 procedure codes in 2024, for 237 Medicare patients. Medicare paid $56,577 for them.

CMS counts 237 Medicare patients who saw Dr. Gernon in 2024. The largest group is 65 to 74, with 130 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 30% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gernon's median patient age at 68, with 41% women.

In 2024, Dr. Gernon wrote 22 Medicare Part D claims for 20 patients. 100% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $92 in total drug cost. In 2021, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Gernon for performance year 2024, reported as part of a group. Dr. Gernon accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gernon as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 14 papers to Dr. Gernon, published from 2013 to 2024. 2013 was the busiest year, with 2. The most frequent topics are Carcinoma, Squamous Cell, DNA-Binding Proteins and Mouth Neoplasms. Dr. Gernon's most frequent co-authors are Ellie G. Maghami, MD, Arya Amini, MD and Robert Suk Kang.

CMS Open Payments shows 19 general payments to Dr. Gernon from 11 drug and device companies from 2016 to 2025. Education make up the largest share, 81% of the total. Intuitive Surgical, Inc. paid the most, $5,016.

Dr. Gernon graduated from University Of Washington School Of Medicine in 2005.

Dr. Gernon is in network with 10 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.